Graftys SA Receives FDA Clearance for Injectable Bone Filler

Graftys SA, a developer of synthetic bone void substitute products, announced it received 510(k) premarket clearance notification from the U.S. Food and Drug Administration for its Graftys Quickset injectable, fast-setting bone void filler, according to a Graftys news release.

Advertisement

The Aix-en-Provence, France-based company now offers a range of resorbable, highly injectable phosphocalcic cements, which includes slower setting Graftys HBS, to address a wide array of clinical needs, according to the release.

Read the Graftys release on Quickset bone filler (pdf).

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.